Severe acute respiratory syndrome coronavirus 2

Purple City Labs Introduces OnSight, a Molecular Assay for In-house Testing of Hop Latent Viroid

Retrieved on: 
Saturday, January 28, 2023
Reverse, PCL, Plant, Breeding, Severe acute respiratory syndrome coronavirus 2, Hop, Chesapeake Utilities, Molecular biology, PCG, Pigment, Vaccine, Purple City Productions

The assay was custom developed for Purple City Genetics (PCG), a California cannabis breeding company, after they had a disappointing experience with outside testing labs.

Key Points: 
  • The assay was custom developed for Purple City Genetics (PCG), a California cannabis breeding company, after they had a disappointing experience with outside testing labs.
  • Purple City Labs conducted a number of proficiency tests comparing OnSight with six other commercially available assays, finding it to be as accurate.
  • “OnSight is an extremely easy and rapid test that has fixed many issues we have experienced when testing our cannabis plants for Hop Latent Viroid.
  • For more information on fast, affordable and effective Hop Latent Viroid testing, reach out to Purple City Labs, Inc.

Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development Conference

Retrieved on: 
Thursday, January 26, 2023
Prader–Willi syndrome, Long COVID, Virus, Pandemic, Psychiatry, CNS, Disease, Peroxisome, MDD, COVID-19, Failure, Coronavirus, Security (finance), Smallpox, University of Alberta, Cancer, Government, Infection, Cell biology, Therapy, Degenerative disease, Orphan drug, RPV, University, Drug development, Fibromyalgia, Conference, SL, Central nervous system, Breakthrough therapy, WNT, Monkeypox, CD40L, FDA, Severe acute respiratory syndrome coronavirus 2, Hydrogen chloride, Risk, Neurology, Autoimmunity, Professor, Research, Pain, Annual report, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Tonix has previously announced that it exercised an option to license the antiviral technology platform.

Key Points: 
  • Tonix has previously announced that it exercised an option to license the antiviral technology platform.
  • A copy of the presentation is available on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com .
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Retrieved on: 
Tuesday, January 24, 2023
Nasal congestion, Virus, Particle-size distribution, Safety, Rhinitis, ANCOVA, Sudden death, COVID-19, Sneeze, Rhinorrhea, Allergen, Therapy, Omicron, Degenerative disease, CT, SAR, Research, Allergic rhinitis, Patient, Nasal mucosa, PCR, Incidence, NASAR, Severe acute respiratory syndrome coronavirus 2, Nasal spray, Pharmaceutical industry

The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).

Key Points: 
  • The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).
  • The interim analysis further showed good tolerability and safety both for Bentrio and the comparator.
  • Participants were randomized at a 1:1 ratio to either receive Bentrio or saline spray via self-administration three times per day, or as needed.
  • “We are very excited about the strong efficacy signals observed with Bentrio at the halfway point of the NASAR seasonal allergic rhinitis trial in Australia,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO.

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

Retrieved on: 
Tuesday, January 17, 2023
University, COVID-19, ALS, Balkans, Severe acute respiratory syndrome coronavirus 2, Safety, TSX, Reproduction, NMOSD, Immunization, PD, Contract research organization, Vaccine, Completeness, Massachusetts General Hospital, Diagnosis, Hypoparathyroidism, Novo Nordisk, MGH, Patient, Toxicology, Coronavirus, University of Sheffield, Immortalised cell line, Clinical trial, Antigen, GMP, Pharmaceutical industry, Fine chemical, Management, Birth control, Medical device, Ludwig & Mayer, Chlamydia

“We have made significant development progress since we initiated six pre-clinical development programs in 2021,” said Dr. Klaus Paulini, Chief Executive Officer of Aeterna.

Key Points: 
  • “We have made significant development progress since we initiated six pre-clinical development programs in 2021,” said Dr. Klaus Paulini, Chief Executive Officer of Aeterna.
  • Aeterna is currently conducting its pivotal Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency (“CGHD”).
  • Phase 3 Study: Bolstered enrollment expected by the replacement of inactive countries/sites and engagement of an additional Clinical Research Organization (CRO).
  • Revenues that may be achieved if we out-license any of those development programs are not considered in our budget and thus provides further upside potential.”

SQI installs two RALI-DX systems in Toronto hospitals to fight the growing respiratory health crisis in Emergency Departments

Retrieved on: 
Wednesday, January 18, 2023
Hospital, Acute respiratory distress syndrome, Degenerative disease, COVID-19, Severe acute respiratory syndrome coronavirus 2, Intubation, UHN, Risk, Patient, Emergency department, Science, University Health Network, Innovation, EDS, Physician, IL-6, Triage, Medical device, Pharmaceutical industry

"This is a timely response to the continuing challenge of COVID-19 and other respiratory diseases," said Andrew Morris, President and CEO of SQI Diagnostics.

Key Points: 
  • "This is a timely response to the continuing challenge of COVID-19 and other respiratory diseases," said Andrew Morris, President and CEO of SQI Diagnostics.
  • "We believe a respiratory triage test will be a vital tool enabling physicians to manage the ongoing respiratory health crisis in our EDs."
  • The number of laboratory confirmed cases of COVID-19 in Ontario began to rise at the beginning of this year according to provincial data.
  • The test was designed by a team of physicians at University Health Network (UHN) and was licensed and further developed by SQI Diagnostics.

Kanazawa University research: Nanoscopic tool assesses alternative COVID-19 prevention

Retrieved on: 
Wednesday, January 18, 2023
AFM, Kanazawa University, X-ray crystallography, COVID-19, Virus, Severe acute respiratory syndrome coronavirus 2, SNAB, Risk, Vaccine, ADE, Nano Letters, Lens, Map, Lim, Antibody, Antibody-dependent enhancement, Microscope, Delta

KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.

Key Points: 
  • KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.
  • Vaccines against coronavirus disease 2019 (COVID-19) developed and produced during the COVID-19 pandemic offer a significant degree of protection.
  • Keesiang Lim from Kanazawa University and colleagues have now succeeded in video-imaging protein–SNAB interactions by means of high-speed atomic force microscopy (HS-AFM).
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Nanoscopic tool assesses alternative COVID-19 prevention

Retrieved on: 
Wednesday, January 18, 2023
AFM, Kanazawa University, X-ray crystallography, COVID-19, Virus, Severe acute respiratory syndrome coronavirus 2, SNAB, Risk, Vaccine, ADE, Nano Letters, Lens, Map, Lim, Antibody, Antibody-dependent enhancement, Microscope, Delta

KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.

Key Points: 
  • KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.
  • Vaccines against coronavirus disease 2019 (COVID-19) developed and produced during the COVID-19 pandemic offer a significant degree of protection.
  • Keesiang Lim from Kanazawa University and colleagues have now succeeded in video-imaging protein–SNAB interactions by means of high-speed atomic force microscopy (HS-AFM).
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Ginkgo Bioworks and XpresCheck Expand CDC's Traveler-Based Genomic Surveillance Program to Detect Influenza Variants

Retrieved on: 
Tuesday, January 17, 2023
Ginkgo Bioworks, Ginkgo, COVID-19, Public health, Biosecurity, Severe acute respiratory syndrome coronavirus 2, DNA, International, Radar, NYSE, Travel, Partnership, Centers for Disease Control and Prevention timeline, Airport, Influenza, Concentric objects, Traveler, CDC, Genomics, Vaccine

BOSTON and NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV-2. The partners continue to grow the program's capabilities to provide an additional source of viral surveillance to inform the selection of influenza vaccine viruses for the forthcoming 2023-2024 flu season.

Key Points: 
  • The partners continue to grow the program's capabilities to provide an additional source of viral surveillance to inform the selection of influenza vaccine viruses for the forthcoming 2023-2024 flu season.
  • Recognizing the high level of seasonal influenza activity this fall and winter, the program is leveraging its large-scale travel biosecurity platform to monitor influenza A and B viruses among arriving international travelers at selected U.S. airports.
  • Samples that test positive for influenza are then shared with CDC for viral genomic sequencing, as well as culturing for further in vitro characterization.
  • Traveler-based pathogen monitoring represents a novel approach to influenza surveillance, complementing CDC's ongoing efforts by providing early insights into global trends in influenza virus evolution.

Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health Announce Collaboration to Implement Biosecurity Capabilities in Ukraine

Retrieved on: 
Tuesday, January 17, 2023
Ginkgo Bioworks, Ginkgo, Uncertainty, COVID-19, Infection, Public health, Biosecurity, Severe acute respiratory syndrome coronavirus 2, DNA, Risk, NYSE, U.S. Army Public Health Center, KYIV, Partnership, Sentinel surveillance, Concentric objects, Organization, Vaccine, Health

BOSTON and KYIV, Ukraine, Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Public Health Center of the Ukraine Ministry of Health today announced a new collaboration to conduct a wastewater testing pilot program in Ukraine with the intent to help provide early warning for infectious disease outbreaks and enable rapid and strategic public health intervention.

Key Points: 
  • Amidst the ongoing COVID-19 pandemic and the strain on health infrastructure in Ukraine due to the war, the risk of infectious diseases spreading in the country has increased.
  • Through this partnership, Ginkgo is building upon the large-scale pathogen monitoring platform developed by its biosecurity and public health unit, Concentric by Ginkgo, to implement a nimble, on-the-ground biosecurity program for monitoring of biological threats found in critical wastewater systems.
  • The program can be utilized to address biosecurity gaps during acute moments of crisis, where public health infrastructure has been affected by adverse circumstances.
  • "We are grateful to be able to partner with the Public Health Center of the Ukraine Ministry of Health to implement this novel response program and provide critical data to help public health leaders make well-informed decisions."

Global Reusable Face Mask Market Report 2022 to 2031 - Major Players Include Respro, Moldex-Metric, Vogmask and idMASK - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 18, 2023
General Health, Health, Other Manufacturing, Manufacturing, Benchmark, Venus, First Nations in Ontario, World Health Organization, Create, Face, Honeywell, Virus, Kimberly-Clark, Severe acute respiratory syndrome coronavirus 2, Cotton, Bacteria, Organization, Infection, Mouth, Growth, Coronavirus, United Nations, Nose, Animal, Marketing, Cosmetics

The "Reusable Face Mask Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Reusable Face Mask Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global reusable face mask market.
  • Major companies operating in the reusable face mask market are introducing new products to sustain their position in the market.
  • The countries covered in the reusable face mask market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.